Literature DB >> 21993994

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Coral Ho1, Chunmei Wang, Sandra Mattu, Giulia Destefanis, Sara Ladu, Salvatore Delogu, Julia Armbruster, Lingling Fan, Susie A Lee, Lijie Jiang, Frank Dombrowski, Matthias Evert, Xin Chen, Diego F Calvisi.   

Abstract

UNLABELLED: Activation of v-akt murine thymoma viral oncogene homolog (AKT) and Ras pathways is often implicated in carcinogenesis. However, the oncogenic cooperation between these two cascades in relationship to hepatocellular carcinoma (HCC) development remains undetermined. To investigate this issue, we generated a mouse model characterized by combined overexpression of activated forms of AKT and neuroblastoma Ras viral oncogene homolog (N-Ras) protooncogenes in the liver by way of hydrodynamic gene transfer. The molecular mechanisms underlying crosstalk between AKT and N-Ras were assessed in the mouse model and further evaluated in human and murine HCC cell lines. We found that coexpression of AKT and N-Ras resulted in a dramatic acceleration of liver tumor development when compared with mice overexpressing AKT alone, whereas N-Ras alone did not lead to tumor formation. At the cellular level, concomitant up-regulation of AKT and N-Ras resulted in increased proliferation and microvascularization when compared with AKT-injected mice. Mechanistic studies suggested that accelerated hepatocarcinogenesis driven by AKT and N-Ras resulted from a strong activation of mammalian target of rapamycin complex 1 (mTORC1). Furthermore, elevated expression of FOXM1/SKP2 and c-Myc also contributed to rapid tumor growth in AKT/Ras mice, yet by way of mTORC1-independent mechanisms. The biological effects of coactivation of AKT and N-Ras were then recapitulated in vitro using HCC cell lines, which supports the functional significance of mTORC1, FOXM1/SKP2, and c-Myc signaling cascades in mediating AKT and N-Ras-induced liver tumor development.
CONCLUSION: Our data demonstrate the in vivo crosstalk between the AKT and Ras pathways in promoting liver tumor development, and the pivotal role of mTORC1-dependent and independent pathways in mediating AKT and Ras induced hepatocarcinogenesis.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993994      PMCID: PMC3269553          DOI: 10.1002/hep.24736

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Phosphorylation and regulation of Raf by Akt (protein kinase B).

Authors:  S Zimmermann; K Moelling
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 3.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

4.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Chunmei Wang; Coral Ho; Sara Ladu; Susie A Lee; Sandra Mattu; Giulia Destefanis; Salvatore Delogu; Antje Zimmermann; Johan Ericsson; Stefania Brozzetti; Tommaso Staniscia; Xin Chen; Frank Dombrowski; Matthias Evert
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

5.  Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

Authors:  Diego F Calvisi; Sara Ladu; Elizabeth A Conner; Daekwan Seo; Jer-Tsong Hsieh; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Hepatol       Date:  2010-09-07       Impact factor: 25.083

Review 6.  The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

Authors:  S Whittaker; R Marais; A X Zhu
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

7.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

Review 8.  Targeted therapy for hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.

Authors:  Alyssa L Kennedy; Jennifer P Morton; Indrani Manoharan; David M Nelson; Nigel B Jamieson; Jeff S Pawlikowski; Tony McBryan; Brendan Doyle; Colin McKay; Karin A Oien; Greg H Enders; Rugang Zhang; Owen J Sansom; Peter D Adams
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

View more
  99 in total

Review 1.  [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].

Authors:  T Longerich
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.

Authors:  Heng Wu; Junyan Tao; Xiaolei Li; Tianpeng Zhang; Lei Zhao; Yao Wang; Lei Zhang; Jun Xiong; Zhi Zeng; Na Zhan; Clifford J Steer; Li Che; Mingjie Dong; Xiaomei Wang; Junqi Niu; Zhuoyu Li; Guiqing Yan; Xin Chen; Guisheng Song
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

3.  Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.

Authors:  Lei Li; Li Che; Kevin M Tharp; Hyo-Min Park; Maria G Pilo; Dan Cao; Antonio Cigliano; Gavinella Latte; Zhong Xu; Silvia Ribback; Frank Dombrowski; Matthias Evert; Gregory J Gores; Andreas Stahl; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

4.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

5.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Authors:  Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2017-07-19       Impact factor: 25.083

6.  Effects of long term low- and high-dose sodium arsenite exposure in human transitional cells.

Authors:  Jianming He; Feng Wang; Fen Luo; Xuedan Chen; Xi Liang; Wenbin Jiang; Zhizhong Huang; Jiafan Lei; Fabo Shan; Xueqing Xu
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

7.  Isoform-specific activation of Akt involvement in hepatocarcinogenesis.

Authors:  Mohamed R Imache; Jean-Michel Pawlotsky; Hervé Lerat
Journal:  Hepat Oncol       Date:  2015-07-28

8.  CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice.

Authors:  Mingming Gao; Dexi Liu
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

9.  EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Authors:  Rossella Pellegrino; Diego F Calvisi; Olaf Neumann; Venkatesh Kolluru; Josephine Wesely; Xin Chen; Chunmei Wang; Torsten Wuestefeld; Sara Ladu; Nahla Elgohary; Justo Lorenzo Bermejo; Bernhard Radlwimmer; Martin Zörnig; Lars Zender; Frank Dombrowski; Matthias Evert; Peter Schirmacher; Thomas Longerich
Journal:  Hepatology       Date:  2014-03-27       Impact factor: 17.425

Review 10.  Mouse models for liver cancer.

Authors:  Latifa Bakiri; Erwin F Wagner
Journal:  Mol Oncol       Date:  2013-02-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.